Micron’s record-setting winning streak ends with a thud

Gravity has come for Micron.

The memory chipmaking specialist has been on an unreal run, rising for a record 12 consecutive sessions before Friday’s plunge.

The stock had been buoyed by the continued drumbeat of positive news regarding the expansion of AI data centers, rising more than 40% during its streak of up days. Its winning streak had pushed shares above Wall Street analysts’ average price target.

The company reports earnings next week.

More Markets

See all Markets

Luke Kawa12h

Broadcom soars on Google’s plans for up to $185 billion in capex this year

Google’s capex guidance is Broadcom’s earnings guidance.

The hyperscaler and search giant said its 2026 capex budget would be between $175 billion and $185 billion, 55% higher than Wall Street had anticipated.

Accordingly, shares of the custom chip specialist soared in after-hours trading and have held onto those gains in early action on Thursday, currently up 5.6% as of 4:35 a.m. ET.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

But the custom chip designer had tumbled after its most recent earnings report, with some analysts attributing the decline to the dearth of new customer announcements. But who needs new customers when your current ones are opening their wallets this much?!?

Alphabet beat earnings and revenue expectations

Accordingly, shares of the custom chip specialist soared in after-hours trading and have held onto those gains in early action on Thursday, currently up 5.6% as of 4:35 a.m. ET.

Broadcom has enjoyed a halo effect from Google’s capex plans and the success of its Gemini 3 model (trained on TPUs the two companies codesigned) over the past year.

Luke Kawa

13h

Qualcomm tumbles after releasing gloomy Q2 guidance thanks to memory chip supply crunch

Q1 results beat expectations, but the memory chip crunch looks to be weighing on the forward outlook.

A crowd of visitors at the Qualcomm ( Qualcomm is an...

Tasha Matsumoto

13h

Stocks continue to slide amid tech sell-off

Investors were once again in risk-off mode as tech and crypto continued to fall.

Chicago Bears fans react during the second half of a game against the Arizona Cardinals at State Farm Stadium on November 03, 2024 in Glendale, Arizona.

Novo and Lilly agree prices are falling — and disagree on what comes next

Novo Nordisk and Eli Lilly are cutting prices to reach more patients — with sharply different expectations about what that means for sales.

J. Edward Moreno14h

Ozempic is no longer the most searched for GLP-1 in the US

Ozempic, the popular diabetes drug made by Novo Nordisk, used to be shorthand for an entire class of diabetes and weight-loss medications. Not anymore.

According to Google Trends data, as of January, more people in the US are searching for Eli Lilly’s weight-loss shot, Zepbound, than Ozempic. At the same time, interest in the word “Ozempic” now sits roughly on par with searches for “peptides,” a catchall term for a booming, loosely regulated category of experimental supplements.

The numbers hint at a cultural shift: Ozempic is no longer the only word people reach for when they think about weight-loss drugs. The market — and the vocabulary around it — is fragmenting.

This shift also reflected in sales numbers. For several quarters now, Lilly’s diabetes and weight-loss drugs have outsold Novo’s, and that gap is expected to widen this year.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.